DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04839237

WithdrawnPhase 2

The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

—

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥28

Primary endpoints

•Body weight, absolute change (kg)•Genotype

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04839237
Org study ID201710832

Timeline

Milestones

Study start2017-12-01actual
Primary completion2020-12-01estimated
Study first posted2021-04-09actual
Last update posted2021-04-09actual
Study completion2021-12-01estimated

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Patients aged 18 to 65 years (to the date of screening)；

2. The newly diagnosed obese patients (BMI greater than 28 kg/m2) or abdominal obesity (male waist circumference is greater than 90cm, female waist is greater than 85cm).

3. Nearly a month have not used weight-related drugs,including various weight-loss drugs,GLP-1 analogs or agonists,metformin, acarbose,insulin,anti hyperthyroid drugs,etc;Or recently used weight-related drugs but the stable dose was more than 1 month,and the drug dose remained constant or decreased during the trial.

4. Weight stable for more than 3 months (weight fluctuations <5%).

Exclusion criteria

1. Pregnant female.

2. Secondary diseases caused by other diseases: including hypothyroidism, increased cortisol, hypothalamic and pituitary lesions caused by obesity, all kinds of drug-induced obesity, and others.

3. Severe cardiovascular and cerebrovascular diseases (heart failure, myocardial infarction, acute hemorrhagic or ischemic encephalopathy), pulmonary heart disease or pulmonary insufficiency, renal failure, severe hepatitis.

4. Combined with acute complications of diabetes such as ketoacidosis, lactic acidosis, hyperosmolar state of diabetes.

5. Nearly a month had surgery, trauma, infection and so on.

6. Limb deformity incomplete, difficult to accurately determine the height, weight and other physical indicators.

7. Poor medication compliance or serious side effects (severe rash, syncope, etc.).

Endpoints (15)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
7
Glycemic / diabetes
3
Other (unclassified)
3
Weight & body composition
2

Weight & body composition

2 endpoints
Primary/protocol endpoint

Weight Change at 3 months

Time frame:baseline and 3 months

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in waist circumference

Time frame:baseline and 3 months

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

3 endpoints
Secondary/protocol endpoint

Change in HbA1c

Time frame:baseline and 3 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in plasma glucose

Time frame:baseline and 3 months

change from baseline, improvement

Secondary/protocol endpoint

Change in insulin

Time frame:baseline and 3 months

change from baseline, improvement

Cardiometabolic biomarkers

7 endpoints
Secondary/protocol endpoint

Change in systolic blood pressure

Time frame:baseline and 3 months

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change in diastolic blood pressure

Time frame:baseline and 3 months

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Secondary/protocol endpoint

Change in lipids-total cholesterol

Time frame:baseline and 3 months

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in lipids-low density lipoprotein cholesterol

Time frame:baseline and 3 months

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in lipids-high density lipoprotein cholesterol

Time frame:baseline and 3 months

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in lipids-triglycerides

Time frame:baseline and 3 months

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in lipids-free fatty acids

Time frame:baseline and 3 months

Free fatty acids, change

change from baseline, improvement

Other (unclassified)

3 endpoints
Primary/protocol endpoint/low confidence

Genotype

Time frame:baseline

descriptive

Secondary/protocol endpoint/low confidence

Change in Uric Acid

Time frame:baseline and 3 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Gut microbiota composition

Time frame:3 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.